02075nam a2200505 i 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.0m     o  d f      cr bn||||||ada101117s1993    mdua    ob   f000 0 eng c  a624651249  aOCLCEbengerdaepncOCLCEdOCLCQdOCLCOdOCLCQdGILDSdOCLCOdOCLCFdOCLCAdGPOdMvI  adlrapcc  an-us---  a0831-C-12 (online)0 aHE 20.3965:136zHE 20.8216:136  aHE 20.3965:13600aAssessing neurotoxicity of drugs of abuse /ceditor: Lynda Erinoff. 1aRockville, MD :bU.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute on Drug Abuse,c1993.  a1 online resource (vi, 281 pages) :billustrations.  btxt  bc2rdamedia  bcr2rdacarrier1 aNIDA research monograph ;v1361 aNIH publication ;vno. 93-3644  aIncludes bibliographical references.  aCRDP Program record.  aDescription based on online resource, PDF version; title from title page (NIDA, viewed April 3, 2019). 0aNeurotoxicologyzUnited States. 0aNeuropharmacologyzUnited States. 0aDrugs of abusexToxicologyzUnited States. 0aDrug abusexHealth aspectszUnited States. 0aNeuroplasticity. 7aNeuropharmacologyxResearch.2fast0(OCoLC)fst01036460 7aNeurotoxicologyxResearch.2fast0(OCoLC)fst01036562 7aUnited States.2fast0(OCoLC)fst012041551 aErinoff, Lynda,eeditor.2 aNational Institute on Drug Abuse,eissuing body.08iPrint version:tAssessing neurotoxicity of drugs of abusew(DLC) 93246201w(OCoLC)29307989 0aNIDA research monograph ;v136. 0aNIH publication ;vno. 93-3644.40uhttps://purl.fdlp.gov/GPO/gpo118900  aBEVbFed Docs  c285676d285676